A retrospective monocenter review of simultaneous pancreas-kidney transplantation

Transplant Proc. 2009 Oct;41(8):3389-92. doi: 10.1016/j.transproceed.2009.09.019.

Abstract

Objective: Herein we have reviewed a consecutive series of simultaneous pancreas-kidney (SPK) transplantations performed at our institution over a 6-year period.

Patients and methods: The study population included 22 patients (15 males and 7 females) who underwent SPK transplantation between 2001 and 2007. The mean recipient age was 47 years (range, 26-63 years). Eighteen patients suffered type 1 and 4 type 2 diabetes mellitus. The mean donor age was 33 years (range, 14-56 years). The mean HLA match was 2.1 (range, 1-5). Immunosuppressive treatment consisted of basiliximab induction followed by tacrolimus, mycophenolate mofetil, and prednisone.

Results: The mean hospital stay was 20 days (range, 11-52 days). After a mean follow-up of 44 months (range, 17-88 months), patient, kidney, and pancreas graft survivals were 86%, 82%, and 73%, respectively. Two patients died in the immediate postoperative period due to, respectively, disseminated intravascular coagulation and pulmonary embolism. A kidney graft was lost due to early hyperacute rejection. Other early complications associated with the pancreas graft included 2 cases of immediate reperfusion defects that led to early vascular thrombosis in 1 patient and a duodenal graft fistula in the other patient; a third patient developed type 2 diabetes mellitus. Beyond the postoperative period, graft loss was limited to 1 case of noncompliance to the immunosuppressive medications and 1 death secondary to pulmonary infection with a functional allograft after 4 years.

Conclusions: SPK transplantation is a valid therapeutic option for patients with insulin-dependent diabetes mellitus and renal failure due to diabetic nephropathy. The main complications of SPK transplantation occur in the immediate postoperative period consequent to vascular or rejection processes.

MeSH terms

  • Adolescent
  • Adult
  • Antibodies, Monoclonal / therapeutic use
  • Basiliximab
  • Blood Glucose / metabolism
  • Cadaver
  • Diabetes Mellitus, Type 1 / surgery*
  • Diabetes Mellitus, Type 2 / surgery
  • Diabetic Nephropathies / surgery*
  • Female
  • Graft Rejection / epidemiology
  • Graft Survival
  • Histocompatibility Testing
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Kidney Transplantation / immunology
  • Kidney Transplantation / statistics & numerical data*
  • Male
  • Middle Aged
  • Pancreas Transplantation / immunology
  • Pancreas Transplantation / statistics & numerical data*
  • Recombinant Fusion Proteins / therapeutic use
  • Retrospective Studies
  • Tissue Donors / statistics & numerical data
  • Treatment Outcome
  • Young Adult

Substances

  • Antibodies, Monoclonal
  • Blood Glucose
  • Immunosuppressive Agents
  • Recombinant Fusion Proteins
  • Basiliximab